Clinical Trial Update: CUE-101with Pembrolizumab for LA-HPV+HNSCCs [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry describes a Phase 2 trial evaluating CUE-101 in combination with Pembrolizumab for locally advanced, HPV-positive head and neck sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CUE-101
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Yale University | Conditions: Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING